Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2019.04.072 | DOI Listing |
Publication Analysis
Top Keywords
comment "secukinumab
4
"secukinumab drug
4
drug survival
4
survival patients
4
patients psoriasis
4
psoriasis multicenter
4
multicenter real-world
4
real-world retrospective
4
retrospective study"
4
comment
1
Similar Publications
Disappointing long-term efficacy of secukinumab in patients with hidradenitis suppurativa: the need for defining long-term outcomes and evaluating treatment combinations.
Br J Dermatol
January 2025
Service de dermatologie, Hôpital Saint Louis, AP-HP, Université Paris Cité, Paris, France.
Interleukin-17 blockade by secukinumab was not effective in controlling lichen planus in a randomized controlled clinical trial.
Br J Dermatol
October 2024
Department of Dermatology, University Medical Center Hospital, TU Dresden, Dresden, Germany.
Comment on: Achieving inactive disease in enthesitis-related arthritis with secukinumab following TNF-inhibitor failure.
Rheumatology (Oxford)
November 2024
Rheumatology Unit, ERN-ReCONNET Center, Meyer Children's Hospital IRCCS, Florence, Italy.
Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
Lancet
February 2024
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!